Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study, we analyzed a clinically annotated cohort of patients with melanoma (n = 144) treated with anti-PD1 ICB, with whole-exome an...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, David, Schilling, Bastian, Liu, Derek, Sucker, Antje, Livingstone, Elisabeth, Jerby-Arnon, Livnat, Zimmer, Lisa, Gutzmer, Ralf, Satzger, Imke, Loquai, Carmen, Grabbe, Stephan, Vokes, Natalie, Margolis, Claire A., Conway, Jake, He, Meng Xiao, Elmarakeby, Haitham, Dietlein, Felix, Miao, Diana, Tracy, Adam, Gogas, Helen, Goldinger, Simone M., Utikal, Jochen, Blank, Christian U., Rauschenberg, Ricarda, von Bubnoff, Dagmar, Krackhardt, Angela, Weide, Benjamin, Haferkamp, Sebastian, Kiecker, Felix, Izar, Ben, Garraway, Levi, Regev, Aviv, Flaherty, Keith, Paschen, Annette, Van Allen, Eliezer M., Schadendorf, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898788/
https://www.ncbi.nlm.nih.gov/pubmed/31792460
http://dx.doi.org/10.1038/s41591-019-0654-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898788/
https://www.ncbi.nlm.nih.gov/pubmed/31792460
http://dx.doi.org/10.1038/s41591-019-0654-5

Ejemplares similares